Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F.
Arrondeau J, et al. Among authors: dumas g.
Invest New Drugs. 2012 Oct;30(5):2046-9. doi: 10.1007/s10637-011-9764-8. Epub 2011 Oct 29.
Invest New Drugs. 2012.
PMID: 22038662